Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Despite global advancements in pediatric critical care, mortality and morbidity in septic shock remain unacceptably high. Although data suggest a reduction in mortality with steroid therapy in refractory shock, specific data for hydrocortisone in pediatrics are limited. The findings of this study would not only be a valuable addition to the existing stats but might also help develop a protocol for the use of hydrocortisone therapy in children with septic shock, seeking an earlier recovery from organ failure, earlier reversal of shock, and lower mortality in children with sepsis and septic shock.

Inclusion Criteria:

• Children of any gender
• Aged 2 month to 12 years
• Diagnosed with septic shock
• Admitted to the pediatric intensive care unit

Exclusion Criteria:

• Known adrenal insufficiency or congenital adrenal hyperplasia
• History of corticosteroid use within the past 7 days
• Terminal illness or "do-not-resuscitate (DNR)" status
• Severe immunocompromise (e.g., advanced malignancy, HIV stage IV)
• Known allergy to hydrocortisone